


Attorney Docket No.: T1566P
 Application No.: 10/505,538
 Filing Date: August 19, 2004
 Page No.: 3

Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A compound of formula (I):



wherein

A, B, D and E are each C or N with the proviso that one or more are N;

R¹ and R² are each independently hydrogen, halogen, hydroxy, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₃₋₇cycloalkyl, C₃₋₅cycloalkylC₁₋₄alkyl, NR⁷R⁸, carboxy, esterified carboxy, C₁₋₆alkyl substituted with a group selected from NR⁷R⁸, carboxy and esterified carboxy, or C₁₋₆alkoxy substituted with a group selected from NR⁷R⁸, carboxy and esterified carboxy;

R³ and R⁴ are each independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl;

R⁵ and R⁶ are, at each occurrence, independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆acyloxy, carboxy, esterified carboxy, CONR⁷R⁸, SO₂R⁷, SO₂NR⁷R⁸, aryl, heteroaryl, heterocyclyl, or C₁₋₆alkyl substituted with a group selected from hydroxy, C₁₋₆alkoxy, C₁₋₆acyloxy, carboxy, esterified carboxy, NR⁷R⁸, CONR⁷R⁸, SR⁷, SO₂R⁷, SO₂NR⁷R⁸, aryl, heteroaryl and heterocyclyl;

or R⁵ and R⁶ and the carbon atom to which they are attached together form a carbocyclic ring of 3 to 6 carbon atoms;

R⁷ and R⁸ are, at each occurrence, independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl or fluoroC₁₋₆alkyl;

or R⁷ and R⁸ and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C₁₋₆alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, a group S(O) or

Attorney Docket No.: T1566P
Application No.: 10/505,538
Filing Date: August 19, 2004
Page No.: 4

S(O)₂, or a second nitrogen atom which will be part of a NH or NR^a moiety where R^a is C₁₋₄alkyl optionally substituted by hydroxy or C₁₋₄alkoxy;
X is an oxygen or sulfur atom or the group =NCN;
Y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; and
n is either zero or an integer from 1 to 3;
or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof.

2. (previously presented) A compound according to claim 1 in which X is O.
3. (currently amended) A compound according to claim 1 ~~or 2~~ in which R³ and R⁴ are hydrogen.
4. (currently amended) A compound according to claim 1, ~~2 or 3~~ in which B is nitrogen and A, D and E are carbon.
5. (currently amended) A compound according to ~~any preceding claim in which~~ claim 1 wherein Y is an aryl group selected from unsubstituted phenyl or naphthyl and phenyl or naphthyl substituted by one or two substituents selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, phenyl, cyano, nitro, pyrazolyl, di(C₁₋₆alkyl)amino, phenoxy, -OCH₂O- and C₁₋₆alkylcarbonyl; or a heteroaryl group selected from pyridyl, thiazolyl, isoxazolyl, oxadiazolyl and pyrazolyl wherein each heteroaryl group is optionally substituted with one or two substituents selected from C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, unsubstituted heteroaryl or phenyl which may be substituted by C₁₋₆alkyl or halogen; or a carbocyclyl group which is a C₅₋₇cycloalkyl radical that is unsubstituted or substituted by a phenyl ring; or a fused-carbocyclyl group which is a C₅₋₇cycloalkyl radical that is fused to a phenyl ring.
6. (currently amended) A compound according to ~~any preceding claim~~ claim 1 wherein R⁵ and R⁶ each independently represent a hydrogen atom or a C₁₋₄alkyl or phenyl group.
7. (currently amended) A pharmaceutical composition comprising a compound according to ~~any preceding claim~~ claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.

Attorney Docket No.: T1566P
 Application No.: 10/505,538
 Filing Date: August 19, 2004
 Page No.: 5

8. (currently amended) A compound according to ~~any one of claims 1 to 6~~ claim 1 or a pharmaceutically acceptable salt or N-oxide thereof for use in a method of treatment of the human or animal body by therapy.

9. (currently amended) Use of a compound according to ~~any one of claims 1 to 6~~ claim 1 or a pharmaceutically acceptable salt or N-oxide thereof for use in the manufacture of a medicament for treating diseases and conditions in which pain and/or inflammation predominates.

10. (previously presented) A method of treating a subject suffering from a disease or condition in which pain and/or inflammation predominates which comprises administering to that subject a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.

11. (new) A compound selected from:

N-Benzyl-*N*-isoquinolin-5-ylurea, *N*-(1,1'-Biphenyl-4-ylmethyl)-*N*-isoquinolin-5-ylurea, *N*-(1,1'-Biphenyl-3-ylmethyl)-*N*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N*-(3-phenylpropyl)urea, *N*-Isoquinolin-5-yl-*N*-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)urea, *N*-[2-(4-Chlorophenyl)ethyl]-*N*-isoquinolin-5-ylurea, *N*-[3,5-bis(Trifluoromethyl)benzyl]-*N*-isoquinolin-5-ylurea, *N*-[3-(3,4-dimethylphenyl)propyl]-*N*-isoquinolin-5-ylurea, *N*-(4-*tert*-Butylbenzyl)-*N*-isoquinolin-8-ylurea, *N*-(4-*tert*-Butylbenzyl)-*N*-isoquinolin-5-ylurea, *N*-(4-*tert*-Butylbenzyl)-*N*-quinolin-5-ylurea, *N*-(3-*tert*-Butylbenzyl)-*N*-isoquinolin-5-ylurea, *N*-[2-(4-*tert*-Butylphenyl)ethyl]-*N*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N*-[3-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N*-[2-[4-(trifluoromethyl)phenyl]ethyl]urea, *N*-(2-Oxidoisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N*-[2-[3-(trifluoromethyl)phenyl]ethyl]urea, *N*-Isoquinolin-5-yl-*N*-[3-[4-(trifluoromethyl)phenyl]propyl]urea, *N*-Isoquinolin-8-yl-*N*-[4-(trifluoromethyl)benzyl]urea, *N*-[3-Fluoro-4-(trifluoromethyl)benzyl]-*N*-isoquinolin-5-ylurea, *N*-[2-Fluoro-4-(trifluoromethyl)benzyl]-*N*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N*-[3-[3-(trifluoromethyl)phenyl]propyl]urea, *N*-Isoquinolin-5-yl-*N*-[4-(trifluoromethoxy)benzyl]urea, *N*-[6-(4-Fluorophenyl)pyridin-3-yl]methyl-*N*-isoquinolin-5-ylurea, *N*-Isoquinolin-8-yl-*N*-[3-[4-(trifluoromethyl)phenyl]propyl]urea, *N*-Quinolin-5-yl-*N*-[3-[4-(trifluoromethyl)phenyl]propyl]urea, *N*-Isoquinolin-8-yl-*N*-[3-[3-(trifluoromethyl)phenyl]propyl]urea, *N*-Quinolin-5-yl-*N*-[3-[3-(trifluoromethyl)phenyl]propyl]urea, *N*-Isoquinolin-8-yl-*N*-[4-(trifluoromethoxy)benzyl]urea, *N*-

Attorney Docket No.: T1566P
 Application No.: 10/505,538
 Filing Date: August 19, 2004
 Page No.: 6

Quinolin-5-yl-*N'*-[4-(trifluoromethoxy)benzyl]urea, *N*-(2,3-Dihydro-1*H*-inden-2-ylmethyl)-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-(4-phenylcyclohexyl)urea, *N*-Isoquinolin-5-yl-*N'*-(6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulen-6-ylmethyl)urea, *N*-Isoquinolin-5-yl-*N'*-(6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulen-7-ylmethyl)urea, *N*-isoquinolin-5-yl-*N'*-{[5-(trifluoromethyl)pyridin-2-yl]methyl}urea, *N*-[(4-*tert*-Butylpyridin-2-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-[(6-*tert*-Butylpyridin-3-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-[(2-*tert*-Butylpyridin-4-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-[(6-*tert*-Butylpyridin-2-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-{[6-(trifluoromethyl)pyridin-3-yl]methyl}urea, *N*-Isoquinolin-5-yl-*N'*-[3-[6-(trifluoromethyl)pyridin-3-yl]propyl]urea, *N*-Isoquinolin-5-yl-*N'*-[3-(1*H*-pyrazol-1-yl)benzyl]urea, *N*-Isoquinolin-5-yl-*N'*-[4-(1*H*-pyrazol-1-yl)benzyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(2-phenyl-1,3-thiazol-5-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(2-thien-2-yl-1,3-thiazol-4-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(4-phenyl-1,3-thiazol-2-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(2-phenyl-1,3-thiazol-4-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[2-(4-phenyl-1,3-thiazol-2-yl)ethyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(5-phenylisoxazol-3-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(3-phenylisoxazol-5-yl)methyl]urea, *N*-(8-Fluoroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N'*-methyl-*N'*-[4-(trifluoromethyl)benzyl]urea, *N'*-Isoquinolin-5-yl-*N*-methyl-*N*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N'*-{1-[4-(trifluoromethyl)phenyl]ethyl}urea, *N*-(1,3-Diphenylpropyl)-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]urea, *N*-[(2-Benzyl-1,3-thiazol-4-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-{[1-(2-methylphenyl)-1*H*-pyrazol-4-yl]methyl}urea, *N*-(3-Methoxyisoquinolin-8-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-Cinnolin-5-yl-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(4-*tert*-Butylbenzyl)-*N'*-cinnolin-5-ylurea, *N*-(3-Cyclohexylpropyl)-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-(6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulen-7-yl)urea, *N*-Isoquinolin-5-yl-*N'*-[4-(trifluoromethyl)benzyl]thiourea, *N*-Isoquinolin-6-yl-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-6-yl-*N'*-[4-(trifluoromethoxy)benzyl]urea, *N*-(3-Methylisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(1-Chloroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-[1-(Dimethylamino)isoquinolin-5-yl]-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(3-Methylisoquinolin-5-yl)-*N'*-[4-(trifluoromethoxy)benzyl]urea, *N*-(3-Methylisoquinolin-8-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(3-Chloroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(3-Methylcinnolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-Cinnolin-5-yl-*N'*-[4-(trifluoromethoxy)benzyl]urea, *N*-(1-hydroxyisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-[4-(trifluoromethyl)benzyl]-*N'*-[3-(trifluoromethyl)isoquinolin-5-yl]urea, *N*-(1-chloro-3-ethylisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-phenyl-*N'*-[quinolin-6-yl]urea, *N*-(2-naphthyl)-*N'*-[quinolin-6-yl]urea, *N*-(4-nitrophenyl)-*N'*-[quinolin-6-yl]urea, *N*-[3,5-bis(trifluoromethyl)phenyl]-*N'*-[quinolin-6-yl]urea, *N*-(4-phenoxyphenyl)-*N'*-[quinolin-6-yl]urea, *N*-(4-

Attorney Docket No.: T1566P
 Application No.: 10/505,538
 Filing Date: August 19, 2004
 Page No.: 7

acetylphenyl)-N'-[quinolin-6-yl]urea, N-benzyl-N'-[quinolin-6-yl]urea, N-[quinolin-6-yl]-N'-[4-(trifluoromethoxy)phenyl]urea, N-(4-cyanophenyl)-N'-[quinolin-6-yl]urea, N-(1,1'-biphenyl-4-yl)-N'-[quinolin-6-yl]urea, N-[4-(dimethylamino)phenyl]-N'-[quinolin-6-yl]urea, N-(1,3-benzodioxol-5-yl)-N'-[quinolin-6-yl]urea, N-cyclohexyl-N'-[quinolin-6-yl]urea, N-[(+/-)-1-phenylethyl]-N'-[quinolin-6-yl]urea, N-(1-Methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(1-Methylisoquinolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea, N-(6,8-Difluoro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[3-Methyl-7-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-(8-Fluoro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(6-Fluoro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(6-Fluoro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea, N-(3-Methylcinnolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea, N-(7-Methoxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(1,3-Dimethylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(7-Chloro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(7-Chloroisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(8-Fluoro-3-methoxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(6-Fluoroisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(6-Fluoroisoquinolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea, N-(7-Fluoroisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(4-Methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[8-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[6-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[7-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[7-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethoxy)benzyl]urea, N-(6-Fluoro-1-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(1-Cyanoisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[1-(Methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-(1-Carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(1-Aminoisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[1-(Hydroxymethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[3-(Methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-(3-Carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[3-(Dimethylamino)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[3-(2-Aminoethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-(8-Methoxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-Isoquinolin-7-yl-N'-[4-(trifluoromethyl)benzyl]urea, N-N'-Diisoquinolin-5-ylurea, N-Isoquinolin-5-yl-N'-[4-(trifluoromethyl)phenyl]urea, N-Isoquinolin-5-yl-N'-[2-(trifluoromethyl)pyrimidin-5-yl]methylurea, Ethyl 3-[[[(isoquinolin-5-ylamino)carbonyl]amino]-2-[4-(trifluoromethyl)benzyl]propanoate, 3-[[[(isoquinolin-5-ylamino)carbonyl]amino]-2-[4-(trifluoromethyl)benzyl]propanoic acid, N-Isoquinolin-5-

Attorney Docket No.: T1566P
Application No.: 10/505,538
Filing Date: August 19, 2004
Page No.: 8

yl-*N'*-[4-(morpholin-4-ylmethyl)benzyl]urea, and *N*-Isoquinolin-5-yl-*N'*-[2-(2-morpholin-4-ylethoxy)-4-(trifluoromethyl)benzyl]urea.